Advertisement

Drugs

pp 1–5 | Cite as

Fruquintinib: First Global Approval

  • Matt Shirley
AdisInsight Report
  • 58 Downloads

Abstract

Fruquintinib (Elunate®) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours. In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies. Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer. This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12(1):14–21.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Zhong H, Bowen JP. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways. Curr Top Med Chem. 2011;11(12):1571–90.CrossRefGoogle Scholar
  3. 3.
    Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–45.CrossRefGoogle Scholar
  4. 4.
    Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486–96.CrossRefGoogle Scholar
  5. 5.
    Chi-Med. Chi-Med announces the approval of fruquintinib capsules for previously treated colorectal cancer in China [media release]. 2018. http://www.chi-med.com/wp-content/uploads/2018/09/a180905.pdf. Accessed 27 Sep 2018.
  6. 6.
    Chi-Med. Chi-Med initiates fruquintinib U.S. clinical trials [media release]. 2017. http://www.chi-med.com/wp-content/uploads/2017/12/a171215.pdf. Accessed 27 Sep 2018.
  7. 7.
    Chi-Med. Cancer therapy collaboration with Lilly [media release]. 2013. http://www.chi-med.com/wp-content/uploads/docArchive/announcements/a131009.pdf. Accessed 27 Sep 2018.
  8. 8.
    Ren Y, Sun Q, Long J, et al. Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models [abstract no. 2089 plus poster]. Cancer Res. 2017;77(13 Suppl):2089.CrossRefGoogle Scholar
  9. 9.
    Cao J, Zhang J, Peng W, et al. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–69.CrossRefGoogle Scholar
  10. 10.
    Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2018;36(12):1207–17.CrossRefGoogle Scholar
  11. 11.
    Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22.CrossRefGoogle Scholar
  12. 12.
    Li K, Li X, Xia S, et al. Pharmacokinetics of fruquintinib in humans [abstract no. PII-116 plus poster]. Clin Pharmacol Ther. 2018;103 (Suppl S1):S86.Google Scholar
  13. 13.
    Zhou S, Shao F, Xu Z, et al. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2017;80(3):563–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations